Skin and soft tissue infections due to Panton-Valentine leukocidin producing Staphylococcus aureus

Medecine et Maladies Infectieuses

Volumn 42, Issue 10, 2012, Pages 488-494

  Gros, C ^a   Yazdanpanah, Y ^a   Vachet, A ^b   Roussel Delvallez, M ^c   Senneville, E ^a   Lemaire, X ^a,d  

^a Dron Hospital   (France)

^b Bacteriology laboratory   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Hospital of Douai   (France)

Author keywords

Panton Valentine leukocidin; S.aureus; Skin and soft tissue infection

Indexed keywords

BETA LACTAMASE INHIBITOR; C REACTIVE PROTEIN; CORTICOSTEROID; FUSIDIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OXACILLIN; PANTON VALENTINE LEUKOCIDIN; PENICILLIN G; PRISTINAMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUTCOME ASSESSMENT; RECURRENT INFECTION; RETROSPECTIVE STUDY; SCREENING TEST; SKIN ABSCESS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT PLANNING;

ADOLESCENT; BACTERIAL TOXINS; CHILD; EXOTOXINS; FEMALE; HUMANS; INFANT; LEUKOCIDINS; MALE; RETROSPECTIVE STUDIES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84868697921     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2012.07.002     Document Type: Article

References (39)

1. Lina G., Piémont Y., Godail-Gamot F., Bes M., Peter M.O., Gauduchon V., et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128-1132.
2. Cribier B., Prévost G., Couppie P., et al. Staphylococcus aureus leukocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. Dermatology 1992, 185:175-180.
3. Couppie P., Cribier B., Prévost G. Leukocidin from Staphylococcus aureus and cutaneous infections: an epidemiologic study. Arch Dermatol 1994, 130:1208-1209.
4. Prevost G., Couppie P., Prevost P., et al. Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995, 42:237-245.
5. Gillet Y., Issartel B., Vanhems P., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
6. del Giudice P., Blanc V., Eacute Tienne J. Methicillin-resistant Staphylococcus aureus infections in private practice: dermatologists in the front line. Ann Dermatol Venereol 2007, 13.
7. Kazakova S.V., Hageman J.C., Matava M., et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005, 352:468-475.
8. Frank A.L., Marcinak J.F., Mangat P.D., et al. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999, 18:993-1000.
9. Naimi T.S., LeDell K.H., Boxrud D.J., et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001, 33:990-996.
10. Gorak E.J., Yamada S.M., Brown J.D. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999, 29:797-800.
11. INSEE. Enquête annuelle de recensement 2005, nombre moyen de personnes par ménages. Disponible: http://www.recensement.insee.fr/chiffresCles.
12. Wiese-Posselt M., Heuck D., Draeger A., et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis 2007, 44:88-95.
13. Lee N.E., Taylor M.M., Bancroft E., et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005, 40:1529-1534.
14. Nathwani D., Morgan M., Masterton R.G., et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008, 61:976-994.
15. Cohen P.R. Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection in participants of athletic activities. South Med J 2005, 98:596-602.
16. Stacey A.R., Endersby K.E., Chan P.C., et al. An outbreak of methicillin resistant Staphylococcus aureus infection in a rugby football team. Br J Sports Med 1998, 32:153-154.
17. Centers for disease control prevention (CDC) Methicillin-resistant Staphylococcus aureus infections among competitive sports participants--Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003, 52:793-795.
18. Ramdani-Bouguessa N., Bes M., Meugnier H., et al. Detection of methicillin-resistant Staphylococcus aureus strains resistant to multiple antibiotics and carrying the Panton-Valentine leukocidin genes in an Algiers hospital. Antimicrob Agents Chemother 2006, 50:1083-1085.
19. Tristan A., Bes M., Meugnier H., et al. Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 2007, 13:594-600.
20. Dumitrescu O., Boisset S., Badiou C., Bes M., Benito Y., Reverdy M.E., et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007, 51:1515-1519.
21. Schneider-Lindner V., Delaney J.A., Dial S., Dascal A., Suissa S. Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom. Emerg Infect Dis 2007, 13:994-1000.
22. Dufour P., Gillet Y., Bes M., et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002, 35:819-824.
23. del Giudice P., Blanc V., de Rougemont A., Bes M., Lina G., Hubiche T., et al. Primary skin abscesses are mainly caused by Panton-Valentine leukocidin-positive Staphylococcus aureus strains. Dermatology 2009, 219(4):299-302.
24. Issartel B., Tristan A., Lechevallier S., Bruyère F., Lina G., Garin B., et al. Frequent carriage of Panton-Valentine leucocidin genes by Staphylococcus aureus isolates from surgically drained abscesses. J Clin Microbiol 2005, 43(7):3203-3207.
25. Yamasaki O., Kaneko J., Morizane S., et al. The association between Staphylococcus aureus strains carrying Panton-Valentine leukocidin genes and the development of deep-seated follicular infection. Clin Infect Dis 2005, 40:381-385.
26. Miller L.G., Perdreau-Remington F., Rieg G. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445-1453.
27. Paydar K.Z., Hansen S.L., Charlebois E.D., et al. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006, 141:850-854.
28. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
29. Lee M.C., Rios A.M., Aten M.F., Mejias A., Cavuoti D., McCracken G.H., et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004, 23:123-127.
30. Young D.M., Harris H.W., Charleobis E.D., et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patient. Arch Surg 2004, 139:947-951. Discussion 951-3.
31. Fridkin S.K., Hageman J.C., Morisson M., et al. Methicillin resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444.
32. Ruhe J.J., Smith N., Bradsher R.W., Menon A. Community-onset methicillin resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007, 44:777-784.
33. Ruhe J.J., Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft-tissue infections caused by methicillin-resistant Staphyloccocus aureus. Antimicrob Agents Chemother 2007, 51:3298-3303.
34. Boelaert J.R., Van Landuyt H.W., Gordts B.Z., et al. Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. Infect Control Hosp Epidemiol 1996, 17:809-811.
35. Kalmeijer M.D., Coertjens H., van Nieuwland-Bollen P.M., et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 2002, 35:353-358.
36. Mody L., Kauffman C.A., McNeil S.A., Galecki A.T., Bradley S.F. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003, 37:1467-1474.
37. Conly J.M., Johnston B.L. Mupirocin - Are we in danger of losing it?. J Infect Dis 2002, 13:157.
38. Schmitz F.J., Lindenlauf E., Hofmann B., et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998, 42:489-495.
39. Haut Conseil de la santé publique Commission spécialisée « Sécurité des Patients : infections nosocomiales et autres événements indésirables liés aux soins et aux pratiques ». Recommandations sur la prise en charge et la prévention des infections cutanées liées aux souches de Staphylococcus aureus résistants à la méticilline communautaires (sarm co) Rapport du groupe de travail décembre 2009.